Brokerages Set Guardant Health, Inc. (NASDAQ:GH) PT at $102.81

Guardant Health, Inc. (NASDAQ:GH) has earned a consensus recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twenty-one have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $102.8095.

GH has been the topic of several research analyst reports. William Blair reissued an “outperform” rating on shares of Guardant Health in a report on Thursday, September 25th. Wells Fargo & Company raised their price objective on Guardant Health from $93.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Evercore ISI set a $105.00 target price on Guardant Health and gave the stock an “in-line” rating in a research report on Monday, January 5th. Guggenheim lifted their price objective on Guardant Health from $85.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Finally, Barclays increased their target price on Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, December 15th.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction on Monday, December 8th. The shares were sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. This trade represents a 37.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the sale, the chief executive officer owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. This trade represents a 4.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 445,123 shares of company stock valued at $46,600,702 over the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

Several hedge funds have recently added to or reduced their stakes in GH. AQR Capital Management LLC lifted its stake in Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after purchasing an additional 25,831 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Guardant Health in the first quarter worth approximately $274,000. Signaturefd LLC lifted its stake in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after acquiring an additional 213 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in Guardant Health by 277.8% during the 2nd quarter. Janney Montgomery Scott LLC now owns 20,574 shares of the company’s stock valued at $1,071,000 after acquiring an additional 15,128 shares during the period. Finally, Trivium Point Advisory LLC purchased a new position in Guardant Health during the 2nd quarter valued at $249,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $117.28 on Tuesday. Guardant Health has a fifty-two week low of $34.88 and a fifty-two week high of $120.74. The company has a market capitalization of $14.78 billion, a P/E ratio of -36.54 and a beta of 1.58. The company has a fifty day moving average of $104.83 and a 200 day moving average of $77.00.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period in the previous year, the company earned ($0.88) earnings per share. Guardant Health’s revenue was up 38.5% compared to the same quarter last year. Analysts forecast that Guardant Health will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.